{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:28:17Z","timestamp":1790785697333,"version":"4.1.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T00:00:00Z","timestamp":1296086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Merck-Serono-Italy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Cetuximab was demonstrated by clinical trials to improve response rate and survival of patients with metastatic and nonresectable colorectal cancer or carcinoma of the head and neck. Appropriate management of skin toxicity associated with epidermal growth factor receptor inhibitor (EGFR-i) therapy is necessary to allow adequate drug administration and to improve quality of life and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>A group of Italian Experts produced recommendations for skin toxicity management using the RAND\/UCLA Appropriateness Method. Statements were generated on the basis of a systematic revision of the literature and voted twice by a panel of 40 expert physicians; the second vote was preceded by a meeting of the panelists.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Skin toxicity included skin rash, skin dryness, pruritus, paronychia, hair abnormality, and mucositis. Recommendations for prophylaxis and therapeutic interventions for each type of toxicity were proposed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>Interventions that were considered appropriate to improve compliance and outcomes of cancer patients treated with EGFR-i were identified.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2010-0298","type":"journal-article","created":{"date-parts":[[2011,1,28]],"date-time":"2011-01-28T04:36:58Z","timestamp":1296189418000},"page":"228-238","source":"Crossref","is-referenced-by-count":98,"title":["Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy"],"prefix":"10.1093","volume":"16","author":[{"given":"Carmine","family":"Pinto","sequence":"first","affiliation":[{"name":"a Medical Oncology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Antonio","family":"Barone","sequence":"additional","affiliation":[{"name":"b Medical Oncology Unit, Gemelli Hospital, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[{"name":"c Dermatology Unit, University of Verona, Verona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvio Grazioso","family":"Russi","sequence":"additional","affiliation":[{"name":"d Radiotherapy Unit, Santa Croce and Carle Hospital, Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Carlo","family":"Merlano","sequence":"additional","affiliation":[{"name":"e Oncology Unit, Santa Croce and Carle Hospital, Cuneo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daris","family":"Ferrari","sequence":"additional","affiliation":[{"name":"f Oncology Unit, San Paolo Hospital, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaristo","family":"Maiello","sequence":"additional","affiliation":[{"name":"g Oncology Unit, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (FG), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,1,27]]},"reference":[{"key":"2021122303222451900_B1","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2004.11.061","article-title":"Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer","volume":"22","author":"Rowinsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/BF00371951","article-title":"Epidermal growth factor and transferrin receptor expression in human embryonic and fetal epidermal cells","volume":"282","author":"Zambruno","year":"1990","journal-title":"Arch Dermatol Res"},{"key":"2021122303222451900_B4","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/sj.jid.5701184","article-title":"The epidermal growth factor receptor system in skin repair and inflammation","volume":"128","author":"Pastore","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2021122303222451900_B5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122303222451900_B6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B7","volume-title":"Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial","author":"Van Cutsem"},{"key":"2021122303222451900_B8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122303222451900_B9","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122303222451900_B10","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122303222451900_B11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial","volume":"11","author":"Folprecht","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122303222451900_B12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122303222451900_B13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122303222451900_B14","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122303222451900_B15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122303222451900_B16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2021122303222451900_B17","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1200\/JCO.2005.07.119","article-title":"Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and\/or recurrent squamous cell carcinoma of the head and neck","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B18","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B19","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study","volume":"23","author":"Burtness","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B20","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.4134","article-title":"Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials","volume":"25","author":"Berlin","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I study of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B22","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4001","article-title":"Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): the EVEREST experience (preliminary data)","volume":"26","author":"Tejpar","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","article-title":"K-ras mutations as an independnet prognostic factor in patients with advanced colorectal cancer treated with cetuximab","volume":"26","author":"Li\u00e8vre","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B24","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/cncr.24088","article-title":"Association of progression-free survival, overall survival, and patients-reported outcomes by skin toxicity and Kras status in patients receiving panitumumab monotherapy","volume":"115","author":"Peeters","year":"2009","journal-title":"Cancer"},{"key":"2021122303222451900_B25","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3892\/or_00000319","article-title":"Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis","volume":"21","author":"Orditura","year":"2009","journal-title":"Oncol Rep"},{"key":"2021122303222451900_B26","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B27","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1200\/JCO.2005.07.120","article-title":"Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.03.008","article-title":"Interobserver agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study","volume-title":"Eur J Cancer","author":"Duffour","year":"2010"},{"key":"2021122303222451900_B29","volume-title":"The RAND\/UCLA Appropriateness Method, \u201cClinical practice guideline development: methodology perspectives","author":"Brook","year":"1994"},{"key":"2021122303222451900_B30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","article-title":"Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck","volume":"19","author":"Bernier","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122303222451900_B31","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","article-title":"High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes","volume":"90","author":"Giro","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021122303222451900_B32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.radonc.2008.09.018","article-title":"Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer","volume":"90","author":"Pryor","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021122303222451900_B33","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ijrobp.2007.05.063","article-title":"Ultrathin hydrocolloid dressing in skin damaged from alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (G.O.N.O. AlteRCC Italian Trial)","volume":"69","author":"Russi","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122303222451900_B34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2008.12.006","article-title":"Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab","volume":"90","author":"Skvortsova","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021122303222451900_B35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li","year":"2009","journal-title":"Target Oncol"},{"key":"2021122303222451900_B36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2133.2009.09214.x","article-title":"Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors","volume":"161","author":"Osio","year":"2009","journal-title":"Br J Dermatol"},{"key":"2021122303222451900_B37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000229752","article-title":"Risk of high-grade skin rash in cancer patients treated with cetuximab\u2014an antibody against epidermal growth factor receptor: systemic review and meta-analysis","volume":"77","author":"Su","year":"2009","journal-title":"Oncology"},{"key":"2021122303222451900_B38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky","year":"2009","journal-title":"Curr Oncol"},{"key":"2021122303222451900_B39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3816\/CCC.2008.n.007","article-title":"Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic\/Dermatologic Cooperation","volume":"7","author":"Racca","year":"2008","journal-title":"Clin Colorectal Cancer"},{"key":"2021122303222451900_B40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1610-0387.2005.05058.x","article-title":"The management of skin reaction in cancer patients receiving epidermal growth factor receptor targeted therapies","volume":"3","author":"Segaert","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"2021122303222451900_B41","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2478\/v10019-008-0022-4","article-title":"Management of cutaneous side effects of cetuximab therapy with vitamin K1 cr\u00e8me","volume":"42","author":"Ocvirk","year":"2008","journal-title":"Radiol Oncol"},{"key":"2021122303222451900_B43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000229751","article-title":"Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147","volume":"77","author":"Jatoi","year":"2009","journal-title":"Oncology"},{"key":"2021122303222451900_B44","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitor","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2021122303222451900_B45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2021122303222451900_B46","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"2021122303222451900_B47","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2008.16.9391","article-title":"Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib","volume":"26","author":"Braiteh","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B48","article-title":"Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC)","volume":"21","author":"Schwartz","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122303222451900_B49","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"2021122303222451900_B51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archderm.138.1.129","article-title":"Follicular toxic effects of chimeric antiepidermal growth factor receptor antibody cetuximab used to treat human solid tumors","volume":"138","author":"Kimyai-Asadi","year":"2002","journal-title":"Arch Dermatol"},{"key":"2021122303222451900_B52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in nonsmall cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"2021122303222451900_B53","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with nonesmall-cell lung cancer","volume":"22","author":"P\u00e9rez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B54","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2006.09.013","article-title":"Nail toxicity associated with epidermal growth factor receptor inhibitor therapy","volume":"56","author":"Fox","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2021122303222451900_B55","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.9127","article-title":"Influence of skin color in the development of erlotinib-induced rash: a report from the SERIES clinic","volume":"25","author":"Lai","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122303222451900_B56","volume-title":"Common terminology criteria for adverse event v. 2.0 1999, v. 3.0 2006, v. 4.0 2009","author":"National Cancer Institute"},{"key":"2021122303222451900_B57","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1600-0625.2008.00715.x","article-title":"A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition","volume":"17","author":"Wollenberg","year":"2008","journal-title":"Exp Dermatol"},{"key":"2021122303222451900_B58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","article-title":"A propsed EGFR inhibitor adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"2021122303222451900_B59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00520-009-0656-9","article-title":"Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients","volume":"18","author":"Romito","year":"2010","journal-title":"Support Care Cancer"},{"key":"2021122303222451900_B60","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"2021122303222451900_B61","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.radonc.2008.10.014","article-title":"Late onset of skin toxicity induced by EGFr-inhibitors","volume":"90","author":"Eriksen","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021122303222451900_B62","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.radonc.2009.03.001","article-title":"Epidermal Growth factor receptor-inhibitors and radiotherapy-induced cutaneous adverse effects: \u201cKoebner-Phenomenon\u201d or radio-dermatitis?","volume":"92","author":"Merlano","year":"2009","journal-title":"Radiother Oncol"},{"key":"2021122303222451900_B63","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00002820-200006000-00010","article-title":"The effects of hydrocolloid dressing and gentian violet on radiation-induced moist desquamation wound healing","volume":"23","author":"Mak","year":"2000","journal-title":"Cancer Nurs"},{"key":"2021122303222451900_B64","first-page":"1","volume-title":"Sepsis and Multiorgan Failure","author":"Bone","year":"1997"},{"key":"2021122303222451900_B65","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"2021122303222451900_B66","first-page":"vii22","volume-title":"Topical application of vitamin K1 cream for cetuximab-related skin toxicities. Ann Oncol","author":"Ocvirk","year":"2009"},{"key":"2021122303222451900_B67","first-page":"e15087","volume-title":"Treatment of cetuximab-associated cutaneous side effects using topical application of vitamin K1 cream. J Clin Oncol","author":"Ocvirk","year":"2009"},{"key":"2021122303222451900_B68","first-page":"e19671","volume-title":"Analysis of the effects of vitamin K1 cream on cetuximab-induced acne-like rash. J Clin Oncol","author":"Radovics","year":"2010"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0298","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0298","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/2\/228\/41852896\/oncolo_16_2_228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/2\/228\/41852896\/oncolo_16_2_228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T04:56:51Z","timestamp":1640235411000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/2\/228\/6400682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,27]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,1,27]]},"published-print":{"date-parts":[[2011,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0298","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,2,1]]},"published":{"date-parts":[[2011,1,27]]}}}